Overview
Cocoa butter is an edible natural fat obtained from the Theobroma cocoa seeds that is predominantly found in dark chocolate . It is a rich source of monounsaturated and saturated fatty acids that mainly contains approximately 33% Oleic Acid, 25% Palmitic Acid, and 33% Stearic acid but does not contain caffeine or theobromine. Fat cocoa solids, including cocoa butter, have lower phenolic content than non-fat cocoa solids but may contain some polyphenols of different structures of flavonoids with antioxidant properties . Cocoa butter is included in chocolate and other food products, and can also be found in over-the-counter skin products such as lotions, creams, and bars intended to maintain skin softness. While cocoa butter has skin moisturizing properties, it was not shown to reduce the likelihood of developing of striae gravidarum, or stretch marks, in a double-blind, randomized clinical trial of women in the first trimester . Still, it is a common active ingredient for prevention of skin dryness in cosmetic and skincare products. Oftentimes cocoa butter is used in over-the-counter pharmaceutical products and suppositories. The lipid-lowering effects of cocoa butter have been studied and investigated, as fatty acid constituents of cocoa butter are known to exhibit lipid-lowering properties. Dyslipidemia is characterized by elevated levels of plasma triglyceride and very-low-density lipoprotein (VLDL) cholesterol due to overproduction of large triglyceride-enriched VLDL cholesterol particles . Cocoa butter has shown to reduce VLDL cholesterol levels in animal studies, suggesting its potential use in lipid disorders.
Indication
Indicated for topical use in over-the-counter skin products for the treatment of skin dryness and reduction of striae gravidarum (stretch marks).
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|
No clinical trials found
No clinical trials found for this drug
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
Walgreens | 0363-0476 | RECTAL | 2211 mg in 1 1 | 7/13/2025 | |
Walgreens | 0363-0476 | RECTAL | 2211 mg in 1 1 | 7/13/2025 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
No TGA approvals found for this drug. |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
---|---|---|---|---|---|
HEMORRHOIDAL SUPPOSITORIES | h.j. sutton industries ltd. | 02446855 | Suppository - Rectal | 88.44 % | 5/20/2016 |
HEMORRHOIDAL SUPPOSITORIES | triad pharmaceuticals | 02290065 | Suppository - Rectal | 85.5 % | 2/1/2007 |
HEMORRHOIDAL SUPPOSITORIES | pharma pac llc | 02382156 | Suppository - Rectal | 85.5 % / W/W | 9/7/2012 |
SUPPO-H 1000MG/SUP | santrel international inc. | 02004720 | Suppository - Rectal | 1 G / SUP | 12/31/1992 |
SUPPO H SUP 1000MG | produits aloex ltee | 02006324 | Suppository - Rectal | 1 G / SUP | 6/27/1996 |
XYRALID HEMORRHOIDAL SUPPOSITORIES | innovus pharmaceuticals inc | 02484021 | Suppository - Rectal | 88.44 % / W/W | N/A |
APZ HEMORRHOIDAL SUPPOSITORIES | apz pharmaceutical corporation | 02396173 | Suppository - Rectal | 85.5 % / W/W | N/A |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
---|---|---|---|---|---|
No CIMA AEMPS (Spain) approvals found for this drug. |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Philippines FDA approvals found for this drug. |
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Saudi SFDA approvals found for this drug. |
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Malaysia NPRA approvals found for this drug. |
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
---|---|---|---|---|---|
No UK EMC drug information found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.